Among patients who did not receive prophylactic G-CSF, there was a higher proportion of patients discontinuing cabazitaxel treatment during cycles 1–2, suggesting G-CSF for neutropenia management may be critical during the early treatment cycles. The gene discussed is CSF3; the disease is neutropenia.